17

Dec2021
PDCI is pleased to announce the release of the 2021 update to the Census of Insurers. The Census of Insurers is available exclusively through the PDCI Market Access Toolkit. PDCI’s Census of Insurers estimates the market share and private covered lives by insurer across Canada. Private payer and access managers ... Read More

17

Dec2021
PDCI releases new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. VOLUME 2, ISSUE 1... Read More

07

Dec2021
In cancer care, patients often face increased anxiety and uncertainty about their future care pathway. This is paired with an immediate need for therapy to treat potentially aggressive disease. Coverage eligibility for THCD varies significantly across Canadian provinces, creating interprovincial differences. Gaps in coverage of THCDs across provinces lead to inequitable ... Read More

20

May2021
ISPOR 2021 runs between May 17-20 with the theme of HEOR: Evolving for Tomorrow's Challenges. During the conference, PDCI Market Access will be presenting a poster titled: Identification of Gaps and Opportunities for Provincial Reimbursement of Oncology Companion Diagnostics in Canada on May 18th 2021 from 11:30:00 AM ... Read More

30

Sep2020
PDCI-PLA-Study-Report-PDCI-Market-Access-Inc.-Connex-Health-Consulting-H3-ConsultingDownload

09

Sep2020
Palmer-Cell-and-Gene-Theraoy-InsightsDownload

26

Feb2020
PDCI is pleased to inform you of the launch of its podcast series, Between the Lines. Between the Lines invites thought leaders and industry experts to share their insights about the trends and controversies that are shaping the pharmaceutical policy ... Read More

13

Feb2020
Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines. Top-Line Summary The PMPRB regulatory changes and Draft ... Read More

21

Nov2019
Pricing changes for Canada’s patented medicines are on their way and stakeholders are anticipating the release of the updated guidelines. How will the guidelines be operationalized? How will the new pharmacoeconomic factors be implemented? In an effort to answer these questions, PDCI has attempted to reverse-engineer the proposed Pharmacoeconomic Value ... Read More

22

Oct2019
PDCI presented a case study on the proposed amendments to the PMPRB regulations in Canada at the 2019 CAPT Conference held by the Canadian Association for Population Therapeutics. The objective of this policy analysis was to estimate the impact of the proposed PMPRB amendments on orphan drug prices. Review our poster ... Read More